Like MetaWorks, Inc.

closed 1/17/2006 via PR Newswire

United BioSource Corporation, acquired MetaWorks, Inc.

synopsis: United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MetaWorks, Inc.
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2017 via BusinessWire

TractManager, acquired HAYES, Inc.

synopsis: TractManager, Inc., the healthcare industry’s largest supplier of strategic sourcing and contract lifecycle management (CLM) solutions, has acquired Hayes, Inc., an industry leader in providing clinically focused, evidence-based research and analysis to health plans, insurers, hospitals, healthcare systems, ACOs, and government agencies.
buyer parent: Arsenal Capital Partners
buyer: TractManager
TractManager’s healthcare-specific application suite serves three out of five U.S. hospitals. Serving the healthcare industry with integrity for more than 30 years, TractManager is the first-mover in strategic sourcing and enterprise contract lifecycle management. "
target: HAYES, Inc.
Hayes, Inc. is an industry leader in providing clinically focused, evidence-based research and analysis to health plans, insurers, hospitals, healthcare systems, ACOs, and government agencies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/4/2015 via PR Newswire

Precision for Value, acquired Redwood Outcomes

synopsis: Precision for Value, a company that supports commercial excellence for global pharmaceutical and life sciences clients through the demonstration and communication of product value and outcomes, announced its acquisition of Redwood Outcomes, a leading international health economics and outcomes research company.
buyer parent: Precision for Medicine
buyer: Precision for Value
Precision for Value supports excellence for global pharmaceutical and life sciences clients through the communication of product value and outcomes. The Precision for Value teams provide clients with services of industry knowledge, demonstrated analytics proficiency, and communications prowess. "
target: Redwood Outcomes
Redwood Outcomes is a Health Economics & Outcomes Research firm. They aim to advance and apply the science of evidence synthesis, integration, and communication to optimize health care decision-making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/12/2018 via BusinessWire

Certara, acquired Analytica Laser

synopsis: Certara, the global leader in model-informed drug development and regulatory science, announced that it has acquired Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the highest level of scientific evidence of the value of medicines and health technologies.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. "
target: Analytica Laser
Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the highest level of scientific evidence of the value of medicines and health technologies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via GlobeNewswire

ExamWorks, Inc., acquired Advanced Medical Reviews

synopsis: ExamWorks Group, Inc., a leading provider of independent medical examinations, peer reviews, Medicare compliance services and other related services, announced the acquisition of Advanced Medical Reviews, Inc., a national peer review provider with a software platform that enables workflow customization and integration with customer software.
buyer: ExamWorks, Inc. (EXAM:$819.57)
ExamWorks, Inc. is a leading provider of independent medical examinations, peer reviews, bill reviews, Medicare compliance service and IME-related services to the insurance and legal industries, third-party administrators, self-insured parties and federal and state agencies. "
target: Advanced Medical Reviews
Advanced Medical Reviews (AMR), one of the country's top medical peer review organizations, delivers services to a diverse group of healthcare and legal organizations, including: health plans, managed care groups, workers' compensation and disability clients, TPA, IPA and Medical Groups.
price ($mm)
$30
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/28/2014 via PR Newswire

Press Ganey Associates, Inc., acquired Dynamic Clinical Systems

synopsis: Press Ganey, the leading patient experience improvement firm, announced the acquisition of Dynamic Clinical Systems, a patient-reported outcomes services and solutions provider. The acquisition expands Press Ganey's Patient Voice portfolio for health care organizations with the ability to collect, measure and analyze patient-reported data.
buyer parent: Vestar Capital Partners
buyer: Press Ganey Associates, Inc. (PGND:$344.32)
Press Ganey partners with more than 10,000 health care organizations worldwide to create and sustain high-performing organizations. The company offers a comprehensive portfolio of solutions to help clients operate efficiently, improve quality, increase market share and optimize reimbursement. "
target: Dynamic Clinical Systems
Dynamic Clinical Systems is the health care industry's most comprehensive and technically advanced provider of patient-reported outcomes services and solutions, offering an survey system that makes self-reported patient survey data and evidence-based protocols accessible at the point of need.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/9/2013 via BusinessWire

IMS Health Incorporated, acquired Pygargus

synopsis: IMS Health, a leading worldwide provider of information, technology and services, has acquired Pygargus, an industry-leading life sciences advisory and analytics firm based in Sweden, to further advance its technology-enabled Real-World Evidence solutions and global RWE footprint.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading worldwide provider of information, technology, and services dedicated to making healthcare perform better. The IMS global technology infrastructure, advanced analytics and proprietary software platforms help clients improve patient outcomes and operate more efficiently. "
target: Pygargus
Pygargus is a leading independent Scandinavian life science consultancy specialized in Real World Outcomes Research, offering expertise in electronic medical records, registry data handling, data integration and scientific project management.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2011 via Company Press Release

ICON Plc, acquired Oxford Outcomes

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. "
target: Oxford Outcomes
Headquartered in Oxford, UK, and with offices in the USA and Canada, Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation.
price ($mm)
$28*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/13/2012 via Company Press Release

Francisco Partners Management LLC, acquired Therapeutic Research Center, Inc.

synopsis: Francisco Partners, a leading technology-focused private equity firm, announced that it has completed a strategic investment in Therapeutic Research Center, a leading provider of drug therapy recommendations, continuing education, training, and data to the healthcare community.
buyer: Francisco Partners Management LLC
Francisco Partners is a leading global private equity firm with offices in San Francisco and London focused exclusively on investments in technology and technology-enabled services businesses. "
target: Therapeutic Research Center, Inc.
Therapeutic Research Center is a research, analytic, and information services organization that provides evidence-based drug therapy recommendations for physicians, pharmacists, pharmacy technicians, and other healthcare professionals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/30/2019 via Company Press Release

Eversana, will acquire Cornerstone Research Group

synopsis: EVERSANA™, the leading independent provider of commercial services to the life science industry, announced an agreement to acquire Canada-based Cornerstone Research Group, Inc. Cornerstone is a global health economic and market access research company supporting pharmaceutical and medical device companies.
buyer parent: Water Street Healthcare Partners
buyer: Eversana
EVERSANA offers a fully integrated and independent commercial services platform designed to solve global pricing, access, reimbursement, adherence and product delivery challenges in the life science sector. "
target: Cornerstone Research Group
Cornerstone is a global health economic and market access research company supporting pharmaceutical and medical device companies. Founded in 2005, Cornerstone’s initial focus was to build on the partners’ experience in health economic research with an emphasis on global cost-effectiveness models.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/12/2020 via PR Newswire

WebMD Corporation, acquired StayWell

synopsis: WebMD Health Corp., an Internet Brands company and the leader in health information services, announced that it has acquired The StayWell Company, a subsidiary of Merck. StayWell is a health empowerment company that enables populations to improve health outcomes through the science of behavior change.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: WebMD Corporation (WBMD:$700.55)
WebMD Health Corp., an Internet Brands Company, is the leading provider of health information services, serving patients, physicians, health care professionals, employers, and health plans through public and private online portals, mobile platforms, and health-focused publications. "
target parent: Merck & Co., Inc.
target: StayWell
StayWell is a health empowerment company that enables populations to improve health outcomes through the science of behavior change. For more than 40 years, the company has been a pioneer in employer well-being and patient education solutions that lower risks and reduce costs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/28/2016 via GlobeNewswire

Sharecare, Inc., will purchase Population Health Business from Healthways, Inc.

synopsis: Sharecare, the digital health company, announced it is acquiring the Population Health business of Healthways, including: Gallup-Healthways Well-Being Index; Innergy Healthier Weight, a collaboration with Johns Hopkins Medicine that provides a high-touch, personalized solution proven to sustain weight loss.
buyer: Sharecare, Inc.
Sharecare develops web applications for communication and organizations. The company is based in the Netherlands. "
seller: Healthways, Inc. (HWAY:$769.95)
Healthways is the largest independent global provider of well-being improvement solutions. Its Population Health business includes Gallup-Healthways Well-Being Index; Innergy Healthier Weight, a collaboration with Johns Hopkins Medicine that provides a high-touch, personalized solution.
price ($mm)
$30
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/11/2016 via PE Hub

Healthcare Services & Solutions LLC, acquired StayWell

synopsis: Healthcare Services & Solutions LLC, a subsidiary of Merck & Co, has acquired a majority stake in StayWell Company LLC. StayWell is a health engagement company that helps its clients engage and educate people to improve health and business results.
buyer parent: Merck & Co., Inc.
buyer: Healthcare Services & Solutions LLC
Healthcare Services & Solutions, LLC (HSS) offers services and solutions that help patients, providers, and payors around the world achieve improved health care outcomes more efficiently and at a lower cost, through cutting-edge illness prevention and wellness programs and care management offerings."
target parent: Vestar Capital Partners
target: StayWell
StayWell is a health engagement company that helps its clients engage and educate people to improve health and business results.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2015 via BNC Analysis

Beecken Petty O'Keefe & Company, acquired Examination Management Services Inc.

synopsis: Beecken Petty O'Keefe & Company has acquired Examination Management Services (EMSI). Based in Scottsdale, Arizona, EMSI is a provider of medical information, risk adjustment and comprehensive investigative services to insurance companies, health insurers and employers.
buyer: Beecken Petty O'Keefe & Company
Beecken Petty O'Keefe & Company ("BPOC") is a Chicago-based private equity firm founded in 1996 to invest in middle-market buyout transactions, recapitalizations and growth platforms in the health care industry. The firm manages over $1 billion of capital. "
target parent: CM Equity Partners, L.P.
target: Examination Management Services Inc.
Examination Management Services, Inc. is a medical information services provider serving health plans, life and property/casualty insurers and employers. They utilize proprietary networks of professionals with technology-enhanced processes to collect and deliver powerful information to clients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2017 via GlobeNewswire

TelaDoc, Inc., acquired Best Doctors, Inc.

synopsis: Teladoc, Inc., the nation’s first and largest telehealth platform, announced the completion of its acquisition of Best Doctors, the world’s leading expert medical consultation company focused on improving health outcomes for the most complex, critical and costly medical issues.
buyer: TelaDoc, Inc. (TDOC:$519.56)
Teladoc, Inc. is the nation’s first and largest telehealth platform. Recognized by MIT Technology Review as one of the “50 Smartest Companies,” Teladoc is forging a new healthcare experience with an innovative portfolio of virtual care delivery solutions. "
target: Best Doctors, Inc.
Best Doctors is the world’s leading medical consultation company that connects individuals facing difficult diagnostic or medical treatment decisions with the best doctors, ranked by impartial peer review in over 450 subspecialties of medicine, to review their diagnosis and treatment plans.
price ($mm)
$440
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/19/2020 via BNC Analysis

M3 USA Corporation, purchased Healthcare Market Research Business from Manthan Systems

synopsis: M3 Global Research announced the acquisition of Manthan's healthcare market research business. India-based Manthan is a cloud analytics company pioneering applications for retail and consumer-facing businesses. Its healthcare division will be rebranded after the acquisition as m360 Research.
buyer parent: M3, Inc.
buyer: M3 USA Corporation
M3 USA (M3 Global Research), named to represent Medicine, Media, and Metamorphosis, was founded to change the world of medicine through full use of the power of the Internet. M3 provides the life science industry with highly targeted interactive marketing, education, content, and research solutions."
seller: Manthan Systems
The acquisition includes the healthcare market research business of Manthan. India-based Manthan is a cloud analytics company pioneering applications for retail and consumer-facing businesses. Its healthcare division will be rebranded after the acquisition as m360 Research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/1/2011 via BNC Analysis

IMS Health Incorporated, acquired SDI Health LLC

synopsis: IMS Health has completed its acquisition of SDI, a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations. "
target parent: LLR Partners
target: SDI Health LLC
SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market.
price ($mm)
$340
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/22/2010 via BusinessWire

M3 USA Corporation, will acquire EMS Research

synopsis: M3 USA, parent company of MDLinx, a leading medical market research firm, has signed an agreement to purchase EU-based EMS Research, a company specializing in quantitative and qualitative market research for clients in healthcare and other vertical markets.
buyer parent: Sony Corporation
buyer: M3 USA Corporation
M3 USA, named to represent Medicine, Media, and Metamorphosis, was founded with the goal of changing the world of medicine through full use of the power of the Internet. M3 provides the life science industry with highly targeted interactive marketing, education, content, and research solutions. "
target: EMS Research
EMS Research (European Marketing Specialists), headquartered in London, England, was founded in 1999 and is Europe’s leading in-house medical fieldwork company. EMS help clients achieve their objectives by delivering vital insight into markets, attitudes, concepts and products.
price ($mm)
rev ($mm)
$6
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 11/13/2007 via PR Newswire

Cegedim Group S.A., acquired 3ES

synopsis: Cegedim Strategic Data, leading provider of Pharmaceutical Market Research has completed its acquisition of 3ES, a CRO member of the AFCRO, specializing in Clinical Studies and post-AMM studies, notably through online tools.
buyer: Cegedim Group S.A. (ENXTPA:CGM:$512.82)
Established as the world's leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). "
target: 3ES
3ES provides multidisciplinary expertise in the medical research field. 3ES has developed their in-house software for managing online studies via Internet, and has received the ANVAR label for "innovating business".
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/18/2007 via PR Newswire

Phoenix Marketing International, acquired JZM Research

synopsis: Phoenix Marketing International has acquired JZM, Inc. (Johnston, Zabor, McManus), a full service marketing research firm based in Durham, North Carolina, that specializes in healthcare research. The company provides research for 7 of the 10 largest global pharmaceutical companies.
buyer: Phoenix Marketing International
Phoenix Marketing International offers advanced advertising and brand measurement along with direct marketing expertise. Phoenix combines primary and syndicated marketing research expertise with database analytics and modeling proficiency. "
target: JZM Research
JZM is a healthcare focused marketing research firm. The company merges existing, proven marketing research techniques with new state-of-the-art technologies for faster and better results for our pharmaceutical, biotech, and other healthcare clients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/17/2006 via PR Newswire

United BioSource Corporation, acquired MetaWorks, Inc.

synopsis: United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MetaWorks, Inc.
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/19/2013 via BusinessWire

Halifax Group, acquired Envision Pharma, Inc.

synopsis: The Halifax Group, a leading middle-market private equity firm, announced that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries.
buyer: Halifax Group
The Halifax Group is a private equity firm that invests between $10 and $40 million alongside owners and managers of established, growing and profitable companies that are leaders in their market niche. "
target parent: Express Scripts Inc.
target: Envision Pharma, Inc.
Envision Pharma, founded in 2001, is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/18/2011 via BNC Analysis

United BioSource Corporation, acquired Arrowhead Electronic Healthcare

synopsis: Bracket, a division of United BioSource Corp. has acquired Arrowhead Electronic Healthcare, a privately-held electronic patient-reported outcome (ePRO) technologies company. Its ePRO-LOG software platform is used in more than 60 countries on smart phones, tablet computers, the Web and text-messaging apps.
buyer parent: Medco Health Solutions, Inc.
buyer: United BioSource Corporation
United BioSource Corporation (UBC) is a global scientific and medical affairs organization comprised of over 1,400 colleagues who design and execute product development and commercialization programs for clients throughout the industry. "
target: Arrowhead Electronic Healthcare
Arrowhead Electronic Healthcare is an electronic patient-reported outcome (ePRO) technologies company. The company advances patient-centric medical decisions by pioneering software solutions that capture and report real-time patient experiences using smartphones, Web, Tablet computers, and SMS.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/18/2009 via BusinessWire

United BioSource Corporation, acquired Healthcare Project Management

synopsis: United BioSource Corporation has announced the acquisition of HPM (Geneva) SA, a Geneva, Switzerland-based provider of drug safety and pharmacovigilance services, further extending UBC’s reach into the European market.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Healthcare Project Management
Healthcare Project Management (HPM) is a contract research organization founded in 1997 to provide clinical research services to industry as well as academia. Our core services are drug safety, medical writing and scientific consultancy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/7/2006 via Company Press Release

United BioSource Corporation, acquired BioCor LLC

synopsis: United BioSource Corporation acquired BioCor LLC, a provider of clinical data services to the pharmaceutical and biotechnology industries. BioCor delivers dedicated clinical data services and medical writing capabilities to support the regulatory approval process for new drugs.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioCor LLC
BioCor provides clinical data services, biostatistics, and medical writing to the pharmaceutical and biotechnology industries. The company is based in Yardley, Pennsylvania.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/6/2006 via

United BioSource Corporation, acquired BioNiche Global Learning

synopsis: United BioSource Corporation has acquired Bioniche Global Learning, a McLean, Virginia-based provider of training and education services to the pharmaceutical and biotechnology industries. Bioniche specializes in developing and implementing international programs for training health care professionals who serve as investigators in clinical research
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioNiche Global Learning
Bioniche Global Learning provides domestic and international rater training and other clinical trial and CME related educational services to the pharmaceutical and biotechnology industries. The Company specializes in psychiatry and other central nervous system diseases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/24/2006 via PR Newswire

United BioSource Corporation, purchased iLearn, an Advanced Learning Management System from IQ Consultancy Group

synopsis: United BioSource Corporation (UBC) today announced the acquisition of iLearn, an Advanced Learning Management System developed by the UK-based provider of eContent solutions, IQ Consultancy. The robust web-based technology allows UBC to offer new enterprise learning services to pharmaceutical and biotechnology clients.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
seller: IQ Consultancy Group
IQ Consultancy Group is an independent provider of eContent solutions, knowledge management solutions and project management services for e-Business. The company is based in Warrington, United Kingdom.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/17/2006 via PR Newswire

United BioSource Corporation, acquired MetaWorks, Inc.

synopsis: United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MetaWorks, Inc.
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/20/2004 via BusinessWire

United BioSource Corporation, acquired MEDTAP International, Inc.

synopsis: United BioSource Corp. formed in early 2003 to provide science and evidence based services and information to the pharmaceutical and life sciences industries, announced that it has acquired MEDTAP International, Inc., a Bethesda, Md.-based provider of health economics and outcomes research services for the pharmaceutical and biotechnology industry.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MEDTAP International, Inc.
MEDTAP(R) International, Inc. is a global health services research firm that conducts patient reported outcomes studies, economic evaluation and modeling studies, policy research and analysis for pharmaceutical companies, managed care organizations, biotechnology firms, medical device and diagnosti
price ($mm)
$14
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
closed 11/30/2009 via BusinessWire

PPD, Inc., acquired BioDuro, LLC

synopsis: PPD, Inc. announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: BioDuro, LLC
BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of over 630 in Beijing, China. Our priority is providing the highest quality, FDA-compliant services at an affordable cost.
price ($mm)
$49
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

Chiltern International Inc., acquired Vigiun

synopsis: Chiltern International Limited, a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paulo, Brazil.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Vigiun
Vigiun is a full service clinical research organization located in Sao Paulo, Brazil.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2009 via BNC Analysis

JLL Partners, acquired Patheon, Inc.

synopsis: JLL Partners Inc. has become the majority shareholder of Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: Patheon, Inc.
Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnology companies.
price ($mm)[EV]
$89 [$300]*
rev ($mm)
$628
EBITDA ($mm)
$82
EV / rev
1.0x
EV / EBITDA
7.4x
closed 2/26/2009 via PR Newswire

ChanTest Corporation, acquired Applied Cell Sciences

synopsis: The leading experts in ion channels and G-protein coupled receptors - key to drug discovery, development, and safety - are now united. ChanTest, the leading provider of ion channel testing services and validated cell lines, announced that it has acquired Rockville, Maryland-based Applied Cell Sciences. ACS is a contract research organization.
buyer: ChanTest Corporation
ChanTest has developed the world’s most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. "
target: Applied Cell Sciences
Applied Cell Sciences delivers high throughput screening reagents and reagent-development services for drug discovery research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/6/2009 via BusinessWire

WIL Research Laboratories, LLC, acquired Midwest BioResearch, LLC

synopsis: WIL Research Laboratories, LLC and WIL Research Holding Company, Inc. announce the acquisition of Midwest BioResearch, LLC. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.
buyer: WIL Research Laboratories, LLC
WIL Research Laboratories, LLC is a contract research organization that provides an interdisciplinary approach to non-clinical toxicology, pharmacology, metabolism and both clinical and non-clinical bioanalytical services. "
target: Midwest BioResearch, LLC
Midwest BioResearch, LLC was founded in 2003 by scientists, directors and managers from major pharmaceutical companies to provide drug disposition and toxicology services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,557.68)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA

Like MetaWorks, Inc.


read more

MetaWorks, Inc.

HAYES, Inc.

Redwood Outcomes

Analytica Laser

Advanced Medical Reviews

Dynamic Clinical Systems

Pygargus

Oxford Outcomes

Therapeutic Research Center, Inc.

Cornerstone Research Group

StayWell

Healthways, Inc.

StayWell

Examination Management Services Inc.

Best Doctors, Inc.

Manthan Systems

SDI Health LLC

EMS Research

3ES

JZM Research

read more

MetaWorks, Inc.

read more

Envision Pharma, Inc.

Arrowhead Electronic Healthcare

Cognitive Drug Research, Ltd.

Healthcare Project Management

Envision Pharma, Inc.

BioCor LLC

BioNiche Global Learning

IQ Consultancy Group

MetaWorks, Inc.

MEDTAP International, Inc.

read more

Bio-Quant, Inc.

BioDuro, LLC

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Vigiun

Patheon, Inc.

Applied Cell Sciences

Midwest BioResearch, LLC

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

Geography
Matching Companies
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
Clarivate Analytics
Clarivate Analytics
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management.
year
2019
rev ($mm)
$964.58
EBITDA ($mm)
$154.61
EBIT ($mm)
($47.97)
Net Income ($mm)
Employees
4515
  • drill down
  • watch
Ticker: NYSE:IQV
 
 
 
 
 
 
 
 
IQVIA
IQVIA
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services.
year
2018
rev ($mm)
$10,412.00
EBITDA ($mm)
$1,950.00
EBIT ($mm)
$809.00
Net Income ($mm)
$259.00
Employees
58000
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3, Inc.
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet.
year
2019
rev ($mm)
$1,127.03
EBITDA ($mm)
$319.84
EBIT ($mm)
$286.78
Net Income ($mm)
$193.56
Employees
6024
  • drill down
  • watch
Ticker: TSE:4483
 
 
 
 
 
 
 
 
JMDC Inc.
JMDC Inc.
JMDC Inc. offers information services. The Company provides medical data statistics, life insurance data statistics, health data platform management, and other services. JMDC provides its services throughout Japan.
year
2019
rev ($mm)
$91.75
EBITDA ($mm)
EBIT ($mm)
$13.68
Net Income ($mm)
$9.40
Employees
441
  • drill down
  • watch
Ticker: AIM:MED
 
 
 
 
 
 
 
 
MedaPhor
MedaPhor
MedaPhor is a global provider of advanced ultrasound training simulators for medical professionals. Founded in 2004, they have headquarters in Cardiff, UK and San Diego, USA, and our customers are some of the world's leading medical institutions.
year
2017
rev ($mm)
$5.48
EBITDA ($mm)
($2.09)
EBIT ($mm)
($2.82)
Net Income ($mm)
Employees
31
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2017
rev ($mm)
$3,467.64
EBITDA ($mm)
$637.81
EBIT ($mm)
$406.82
Net Income ($mm)
$252.97
Employees
34651
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch